HONG KONG SAR –
Media OutReach Newswire – 22 April 2025 – CK Life Sciences Int’l., (Holdings) Inc. (“the Firm”) introduced that the Firm shall be presenting new information from its most cancers vaccine analysis pipeline on the 2025 American Affiliation for Most cancers Analysis (AACR) Annual Assembly in Chicago, USA.
The AACR Annual Assembly is a gathering central to the worldwide most cancers analysis group, bringing collectively scientists, clinicians, different healthcare professionals, survivors, sufferers and advocates yearly to share the most recent breakthroughs and developments in most cancers science and medication. Final 12 months, the 2024 Annual Assembly attracted 23,000 in-person attendees and 6,700 on-line individuals from 78 nations.
Lately, CK Life Sciences has commonly participated on the AACR Annual Assembly. The 2025 Annual Assembly shall be held from 25-30 April. On the occasion, CK Life Sciences will exhibit posters highlighting information from preclinical research of investigational most cancers vaccines packages concentrating on (i)
PRAME (Preferentially Expressed Antigen in Melanoma), (ii)
PD-L1 (programmed cell dying ligand 1), (iii)
B7-H3 (B7 homolog 3) and (iv)
Claudin 6 proteins, respectively.
PRAME is a protein extremely expressed in a number of cancers, together with melanoma, liver most cancers and leukemia.
PD-L1 is likely one of the most essential immune checkpoint proteins that’s extremely expressed in most cancers cells to dam T cell activation within the tumour microenvironment.
B7-H3 is one other immune checkpoint protein that modulates T cell responses and is commonly overexpressed in most cancers.
Claudin 6 is a good junction protein that regulates epithelial barrier integrity and is overexpressed in cancers like breast most cancers, lung most cancers and endometrial most cancers, the place it’s related to tumour development and metastasis.
As well as, CK Life Sciences shall be co-presenting with our analysis collaborator two posters showcasing our
Synthetic Intelligence (AI)-empowered platform for designing most cancers vaccines.
“CK Life Sciences is happy with the preclinical efficacy outcomes of its investigational most cancers vaccines concentrating on PRAME, PD-L1, B7-H3 and Claudin 6 proteins, and we hope to additional advance the analysis & improvement of those and different most cancers vaccines. We’re additionally excited concerning the progress achieved in our efforts to develop an AI platform geared toward designing most cancers vaccines which might be extra prone to be immunogenic and clinically efficient,” stated Melvin Toh, Vice President and Chief Scientific Officer at CK Life Sciences.
Dr. Toh continued, “CK Life Sciences is set to speed up its R&D to learn most cancers sufferers. At the moment, plenty of therapeutic most cancers vaccines are in medical and discovery/preclinical analysis phases. Amongst them, seviprotimut-L, a most cancers vaccine already within the remaining analysis stage, is being examined for the adjuvant therapy of stage IIB or IIC melanoma following definitive surgical resection.
DETAILS ON POSTER PRESENTATIONS:
- Summary 853: PDL1-PRAME twin antigen most cancers vaccine inhibits melanoma progress in syngeneic mouse mannequin and induces antigen-specific immune responses
Authors: Kin-Tak Chan, Hsin-Wei Chen, Pi-Hui Liang, You-Yu Lin, Tristan Zhang, Melvin Toh
Session Class: Medical Analysis
Session Title: Vaccines and Cell Therapies
Session Date and Time: 4/27/2025 2:00 PM – 5:00 PM
Location: Poster Part 35
Poster Board Quantity: 9
- Summary 3533: Claudin 6 vaccines successfully inhibit tumor progress in a syngeneic mouse colon most cancers mannequin
Authors: Na Wang, Melvin Toh, Hong Wang
Session Class: Immunology
Session Title: Vaccines, In Situ Vaccines, and Vaccine Mixtures
Session Date and Time: 4/28/2025 2:00 PM – 5:00 PM
Location: Poster Part 39
Poster Board Quantity: 9
- Summary 3536: Synergistic results of mixed PD-L1 and B7-H3 fusion protein vaccination in a mouse mannequin of pancreatic most cancers
Authors: Kenneth Nansheng Lin, Melvin Toh, Hong Wang
Session Class: Immunology
Session Title: Vaccines, In Situ Vaccines, and Vaccine Mixtures
Session Date and Time: 4/28/2025 2:00 PM – 5:00 PM
Location: Poster Part 39
Poster Board Quantity: 12
- Summary 3538: The event of neoantigen-derived peptide vaccine pushed by AI epitope design and laptop assisted epitope enhancement
Authors: Chi Han Samson Li, Hong Wang, Kin Tak Chan, Genwei Zhang, Jiewen Du, Lipeng Lai, Melvin Toh
Session Class: Immunology
Session Title: Vaccines, In Situ Vaccines, and Vaccine Mixtures
Session Date and Time: 4/28/2025 2:00 PM – 5:00 PM
Location: Poster Part 39
Poster Board Quantity: 14
- Summary 3649: Synthetic intelligence accelerates shared neoantigen peptide most cancers vaccine improvement
Authors: Genwei Zhang, Jiewen Du, Xiangrui Gao, Zhenghui Wang, Qingxia Zhang, Tongren Liu, Dong Chen, Chi Han Samson Li, Kin Tak Chan, Hong Wang, Melvin Toh, Lipeng Lai
Session Class: Bioinformatics/ Computational Biology/ Programs Biology/ Convergent Science
Session Title: Synthetic Intelligence and Machine Studying for Therapeutic Election and Discovery
Session Date and Time: 4/28/2025 2:00 PM – 5:00 PM
Location: Poster Part 45
Poster Board Quantity: 11
The total abstracts can be found within the AACR On-line Itinerary Planner, which could be accessed at: https://www.abstractsonline.com/pp8/#!/20273
DISCLAIMER
This press launch might comprise forward-looking statements concerning the Group’s analysis and improvement tasks which can contain dangers and uncertainties. Precise outcomes might differ materially from expectations mentioned in such forward-looking statements.
All info on this press launch is for normal reference solely and isn’t meant as funding recommendation or medical recommendation. CK Life Sciences Int’l., (Holdings) Inc. doesn’t warrant or characterize, specific or implied, as to the accuracy, completeness or up to date standing of such info. No legal responsibility shall be accepted for any loss or injury howsoever arising from or in reliance upon such info.
Copyright ©2025 CK Life Sciences Int’l., (Holdings) Inc. All rights reserved.
Hashtag: #CKLifeSciences #CancerVaccines #R&D #Pharmaceutical #AmericanAssociationforCancerResearch #AACR #PRAME #PD-L1 #B7-H3 #Claudin6Proteins #Melanoma #AI
The issuer is solely liable for the content material of this announcement.
